EDAP TMS S.A. (EDAP)
NASDAQ: EDAP · IEX Real-Time Price · USD
7.28
-0.12 (-1.62%)
Apr 26, 2024, 4:30 PM EDT - Market closed
EDAP TMS Revenue
In the year 2023, EDAP TMS had annual revenue of $67.14M with 14.52% growth. Revenue in the quarter ending December 31, 2023 was $21.79M with 30.34% year-over-year growth.
Revenue (ttm)
$67.14M
Revenue Growth
+14.52%
P/S Ratio
4.02
Revenue / Employee
$218,686
Employees
307
Market Cap
270.12M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 67.14M | 8.51M | 14.52% |
Dec 31, 2022 | 58.63M | 8.55M | 17.08% |
Dec 31, 2021 | 50.07M | -733.45K | -1.44% |
Dec 31, 2020 | 50.81M | 344.40K | 0.68% |
Dec 31, 2019 | 50.46M | 5.42M | 12.05% |
Dec 31, 2018 | 45.04M | 2.14M | 4.99% |
Dec 31, 2017 | 42.90M | 5.42M | 14.46% |
Dec 31, 2016 | 37.48M | 2.45M | 6.98% |
Dec 31, 2015 | 35.03M | 2.62M | 8.09% |
Dec 31, 2014 | 32.41M | -705.63K | -2.13% |
Dec 31, 2013 | 33.11M | -1.27M | -3.69% |
Dec 31, 2012 | 34.38M | 5.52M | 19.14% |
Dec 31, 2011 | 28.86M | -2.84M | -8.96% |
Dec 31, 2010 | 31.70M | -3.98M | -11.17% |
Dec 31, 2009 | 35.68M | 3.55M | 11.06% |
Dec 31, 2008 | 32.13M | -508.42K | -1.56% |
Dec 31, 2007 | 32.64M | 5.97M | 22.39% |
Dec 31, 2006 | 26.66M | 2.08M | 8.44% |
Dec 31, 2005 | 24.59M | -5.46M | -18.18% |
Dec 31, 2004 | 30.05M | 6.79M | 29.19% |
Dec 31, 2003 | 23.26M | 2.32M | 11.06% |
Dec 31, 2002 | 20.95M | -356.44K | -1.67% |
Dec 31, 2001 | 21.30M | -4.21M | -16.50% |
Dec 31, 2000 | 25.51M | 5.04M | 24.64% |
Dec 31, 1999 | 20.47M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Vanda Pharmaceuticals | 192.64M |
Sutro Biopharma | 153.73M |
Nanobiotix | 40.23M |
Inovio Pharmaceuticals | 832.01K |
Opthea | 385.28K |
EDAP News
- 4 days ago - EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting - GlobeNewsWire
- 6 weeks ago - EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024 - GlobeNewsWire
- 7 weeks ago - EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference - GlobeNewsWire
- 7 weeks ago - EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis - GlobeNewsWire
- 2 months ago - EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues - GlobeNewsWire
- 3 months ago - EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements - GlobeNewsWire
- 4 months ago - EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer - GlobeNewsWire
- 4 months ago - EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer - GlobeNewsWire